



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, March 6, 2020

In accordance with Article 226 of the recast Spanish Securities Market Act (*Ley del Mercado de Valores*), is hereby reported the following:

INSIDE INFORMATION

The Company reports that its subsidiary Genomica, S.A.U., the molecular diagnosis company belonging to Group Pharma Mar, has obtained today the “CE” conformity marking of its COVID-19 coronavirus diagnostic kits. The “CE” conformity marking certifies that Genomica complies with the essential requirements described in Directive 98/79/EC on *in vitro* diagnostic medical devices. After obtaining the “CE” conformity marking, the referred kits are now commercially available for diagnostic use.

Please find attached press release that will be distributed to the media today.

PharmaMar Group's GENOMICA diagnostic kits for COVID-19 coronavirus receive CE conformity marking

- **GENOMICA will market two products, both validated in clinical samples and with the CE conformity marking:**
 - **CLART[®] COVID-19 (based on GENOMICA's CLART[®] technology). This technology is capable of simultaneously analyzing 96 samples in less than 5 hours**
 - **qCOVID-19 (based on Real Time technology).**
- **GENOMICA is the first Spanish company to obtain the CE marking for the diagnosis of COVID-19 coronavirus.**

Madrid, March 6th, 2020.- PharmaMar (MSE:PHM) has announced that GENOMICA, the molecular diagnostics Company belonging to the PharmaMar Group, has obtained the CE conformity marking for its COVID-19 (SARS-CoV-2) coronavirus diagnostic kits. The CE conformity marking certifies that GENOMICA meets the essential requirements described in Directive 98/79/EC on *in vitro* diagnostic medical devices.

GENOMICA has successfully completed the tests carried out on patient samples, in collaboration with the Carlos III Health Institute, from Madrid. GENOMICA diagnostic kits are highly sensitive and specific in detecting the coronavirus COVID-19, so the virus could be detected even before the patient shows symptoms.

The kits are now available commercially, and these being compatible with the two most widely used diagnostic technologies in hospitals and healthcare centers: CLART[®] from GENOMICA and Real Time PCR.

CLART[®] technology has the capacity to simultaneously analyze 96 patient samples in less than 5 hours, making it a diagnostic option for screening of the virus within the population.

GENOMICA is already in contact with the different health authorities to provide these diagnostic kits given the demand generated by the health emergency due to the COVID-19 infection.

In addition, GENOMICA already has commercial agreements in more than 30 countries, including China, where it can now start distributing these kits.



With extensive experience in the detection of respiratory pathogens, the Company currently markets a diagnostic kit for the detection of 21 different viruses associated with respiratory diseases, including the three most frequently detected coronaviruses in humans (HCoV-229E, HCoV-OC43 and HCoV-NL63). Coronaviruses are an extended family of viruses that can cause the common cold, but also serious diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS).

Due to this global health emergency, reliable diagnostic tools are needed to have a rapid response, to quickly provide adequate treatment to patients and to prevent the spread of the virus to the general population.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About GENOMICA

GENOMICA is highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in Madrid, GENOMICA is 100% owned by PharmaMar. It is our mission to improve the present molecular diagnostics tools and the human identification methods through reliability and automation.

Our main objective is to maintain leadership in genomics applications within the Spanish market, and to internationally extend our activities in the area of Molecular Diagnostics by means of the design, development, automation, and commercialization of new diagnostic applications of our innovative technological platform, Clinical Arrays Technology, CLART®.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com